Drug Profile
Research programme: small molecule therapeutics - Philogen/The Scripps Research Institute
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Philogen; The Scripps Research Institute
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Unspecified in Switzerland
- 28 Feb 2022 No recent reports of development identified for research development in Unspecified in USA
- 08 Jan 2018 Philogen and The Scripps Research Institute agree to co-develop small molecule therapeutics for Undefined indications